Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay Patents (Class 435/7.1)
  • Patent number: 10665440
    Abstract: A method comprises: obtaining a precursor mass-to-charge value, (m/z)p, of a target precursor ion having formula [M+2A]2+, M being a peptide molecule and A being one or more adducts; generating ions from a sample by an ion source; purifying and fragmenting ions comprising the (m/z)p, thereby generating a plurality of MS-2 species; co-purifying and co-fragmenting a selected subset of the MS-2 species, thereby generating a plurality MS-3 species, wherein each selected MS-2 species is a y-type ion species comprising a respective (m/z)f that is greater than (m/z)p; mass analyzing the MS-3 species and selecting a subset thereof, each selected MS-3 species comprising a respective (m/z)g that satisfies a mass-to-charge selection criterion; and determining a quantity of the peptide from a summation of mass spectral intensities corresponding to the selected MS-3 species.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: May 26, 2020
    Assignee: THERMO FINNIGAN LLC
    Inventor: Philip M. Remes
  • Patent number: 10662423
    Abstract: Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: May 26, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Darren E. Higgins, Michael N. Starnbach, Todd Gierahn, Nadia R. Roan
  • Patent number: 10654930
    Abstract: The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis, in a subject. The composition in some embodiments of the invention is an immunoglobulin derived Fc fragment which binds and partially antagonizes the action of CD16.
    Type: Grant
    Filed: February 26, 2017
    Date of Patent: May 19, 2020
    Assignee: B. G. Negev Technologies And Applications Ltd., at Ben-Gurion University
    Inventor: Rachel Lichtenstein
  • Patent number: 10656146
    Abstract: The present invention relates to methods for detecting polymeric analytes, especially biopolymers, and sensors for detecting the polymeric analytes. The present invention uses magnetic beads in a rotating magnetic field to provide a visual detection of the presence of a polymeric analyte, such as nucleic acids, lipids, polysaccharides, proteins, etc. When a polymeric analyte binds to the magnetic beads, application of a rotating magnetic field to the beads results in unique pinwheel formations. Without the presence of the polymeric analyte, the movement of the magnetic beads induced by the rotating magnetic field differs significantly from the pinwheel formations. The pinwheel, therefore, is used to detect the presence of polymeric analytes.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: May 19, 2020
    Assignee: University of Virginia Patent Foundation
    Inventors: James P. Landers, Daniel C. Leslie
  • Patent number: 10656164
    Abstract: A method of determining risk of preterm labor in an asymptomatic pregnant woman can include: obtaining a vaginal fluid sample from an asymptomatic pregnant woman; contacting the vaginal fluid sample with a PAMG-1 antibody that binds with PAMG-1; detecting whether the PAMG-1 antibody binds with PAMG-1 in the vaginal fluid sample to form a PAMG-1-antibody complex; and providing the determined risk to the pregnant woman. When the PAMG-1-antibody complex forms, the asymptomatic pregnant woman is determined to be susceptible to preterm labor because PAMG-1 is detected in the vaginal sample. When the PAMG-1-antibody complex does not form, the asymptomatic pregnant woman is determined to be not susceptible to preterm labor because the PAMG-1 is not detected in the vaginal sample.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 19, 2020
    Assignee: Qiagen Sciences, LLC
    Inventors: Ruben Salinas, Anthony Ausiello
  • Patent number: 10646555
    Abstract: Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby argininosuccinate synthetase or PEGylated argininosuccinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 12, 2020
    Assignee: BioRegency, Inc.
    Inventors: Stanislav I. Svetlov, Victor Prima, Alvin Wang, Gabriel Molina, Kevin Ka-wang Wang
  • Patent number: 10648038
    Abstract: The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: May 12, 2020
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: Min Yang, Simon Steward Jones
  • Patent number: 10640597
    Abstract: In a first aspect, the present disclosure relates to a method for immobilizing a molecularly imprinted polymer onto a substrate, comprising providing a substrate having an amorphous carbon surface; and grafting the molecularly imprinted polymer onto the amorphous carbon surface.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 5, 2020
    Assignees: IMEC VZW, Universiteit Hasselt
    Inventors: Anitha Ethirajan, Evelien Kellens
  • Patent number: 10633455
    Abstract: The present invention provides methods for the diagnosis and/or treatment of chronic kidney disease, immune complex-mediated GN, rheumatoid arthritis, and pulmonary fibrosis, and methods for identifying compounds for such therapeutic use.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 28, 2020
    Assignee: University of Valencia
    Inventors: Juan Saus, Fernando Revert, Ramón Merino Pérez, Jesús Merino Pérez, Francisco Revert-Ros
  • Patent number: 10634681
    Abstract: Disclosed are a method for immunologically measuring cardiac troponin in a biological sample, in which the formation of an immunological complex of cardiac troponin with an antibody specifically binding thereto is performed in the presence of a divalent cation at 4 mmol/L or more; and a kit for measuring cardiac troponin, comprising an antibody specifically binding to cardiac troponin, and a buffer containing a divalent cation at a high concentration. According to the method or the kit, a stable and highly-accurate measured value can be obtained without being affected by interfering substances in a specimen regardless of the type of specimen.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: April 28, 2020
    Assignee: LSI MEDIENCE CORPORATION
    Inventor: Yoshikazu Okamura
  • Patent number: 10620220
    Abstract: The invention provides a method detecting free light chains (FLCs) comprising: (i) providing a sample from a subject; (ii) mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii) passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv) detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 14, 2020
    Assignee: The Binding Site Limited
    Inventor: Graham Peter Mead
  • Patent number: 10620225
    Abstract: The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: April 14, 2020
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Patent number: 10611811
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • Patent number: 10604778
    Abstract: The invention is the products and methods associated with purifying overexpressed recombinant recombinases from a host cell line resulting in an un-tagged protein of interest without any additional, non-native amino acids. The invention employs at least one DNA vector that co-expresses a tagged fusion protein and the recombinase protein with the recombinase protein having an affinity for binding to the the tagged fusion protein. Isolation methods of the recombinase protein include the targeting of the tagged fusion protein.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 31, 2020
    Assignee: IDEA SEED, LLC
    Inventor: Michael Longo
  • Patent number: 10609057
    Abstract: A method for detecting intrusion is provided using a combination of two AIS algorithms: Negative Selection Algorithm (NSA) and Dendritic Cell Algorithm (DCA). The method includes the following steps, or some functional subset of these steps: periodic monitoring of a data processing system for anomalous behavior that may indicate the presence of an intruder or an undesirable software; using the NSA for the generation of a population of detectors that are used for detecting anomalies in the monitored system via a matching criterion; using the DCA (which runs in parallel to the NSA) to sample traffic and signals coming in or out of the data processing system; using an aggregation system to combine the individual decisions of the NSA and the DCA to form a single final decision.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: March 31, 2020
    Assignee: Research Foundation of the City University of New York
    Inventors: Obinna Igbe, Tarek Saadawi, Ihab Darwish
  • Patent number: 10597649
    Abstract: Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: March 24, 2020
    Assignee: Oligomerix, Inc.
    Inventors: James G. Moe, Eliot J. Davidowitz, Patricia Lopez
  • Patent number: 10596227
    Abstract: Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: March 24, 2020
    Assignee: United Kingdom Research and Innovation
    Inventors: Michal Minczuk, Monika A. Papworth, Aaron Klug
  • Patent number: 10597664
    Abstract: The present invention is directed to the cells, compositions and methods for the production of recombinant protein. In particular, the invention is directed to a production process for obtaining high levels of soluble recombinant CRM197 protein from E. coli. Cells preferably contain one or more mutations of disulfide reductase genes, so that disulfide reductase activity is reduced. The invention also relates to purification method for CRM197 as well as characterization of properly folded CRM197 protein.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 24, 2020
    Assignee: Fina BioSolutions, LLC
    Inventors: Natalia Oganesyan, Andrew Lees
  • Patent number: 10598589
    Abstract: The present disclosure relates to a method of analysis by an optical marker, including: irradiating a broadband light source onto a spherical dielectric material; measuring an interference spectrum of reflected light from the spherical dielectric material; and analyzing the reflected light using thin-film interference theory.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 24, 2020
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Myunghwan Choi, YongJae Jo, Junhwan Kwon
  • Patent number: 10590409
    Abstract: A method and a device are provided for facilitating the disaggregation of a plurality of solid phase substrate as the plurality of solid phase substrate are transferred from a first location to a second location. A plurality of solid phase substrate are deposited at the first location and a plurality of particles are added to the plurality of solid phase substrate. A force is generated to draw the plurality of solid phase substrate from the first location to a second location. The plurality of particles causes clumps of the plurality of solid phase substrate to break apart as the plurality of solid phase substrate are moved in response to the force.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 17, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David J. Beebe, David J. Guckenberger, Jr., Hannah M. Pezzi
  • Patent number: 10588953
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Grant
    Filed: December 18, 2016
    Date of Patent: March 17, 2020
    Assignee: AGILVAX, INC.
    Inventors: Federica Cavallo, Stefania Lanzardo, Laura Conti, John P. O'Rourke, Federica Pericle
  • Patent number: 10571455
    Abstract: Methods are described for measuring the amount of a vitamin B2 in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying vitamin B2 in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 25, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Changming Yang, Sum Chan
  • Patent number: 10562977
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali Wang, Lianshan Zhang, Jindong Liang, Ang Li, Fanglong Yang
  • Patent number: 10556218
    Abstract: The present invention provides a formulation to link protein to a solid support that comprises one or more proteins, Oligo-dT and one or more non-volatile, water-soluble protein solvents, solutes or combination thereof in an aqueous solution. Further provided is a method of attaching a protein to a surface of a substrate. The formulations provided herein are contacted onto the substrate surface, printed thereon and air dried. The substrate surface is irradiated with UV light to induce thymidine photochemical crosslinking via the thymidine moieties of the Oligo-dT.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: February 11, 2020
    Assignee: PURE TRANSPLANT SOLUTIONS L.L.C.
    Inventor: Michael E. Hogan
  • Patent number: 10559713
    Abstract: A light-emitting device including a substrate, three-dimensional semiconductor elements resting on the substrate, at least one shell at least partially covering the lateral walls of the semiconductor element, the shell including an active area having multiple quantum wells, and an electrode at least partially covering the shell, at least a portion of the active area being sandwiched between the electrode and the lateral walls of the semiconductor element. The active area includes an alternation of first semiconductor layers mainly including a first element and a second element and of second semiconductor layers mainly including the first element and the second element and further including a third element. In at least three of the layers, the mass concentration of the third element increases in the portion of the active layer as the distance to the substrate decreases.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: February 11, 2020
    Assignee: Commissariat à l'Énergie Atomique et aux Énergies Alternatives
    Inventors: Ivan-Christophe Robin, Amélie Dussaigne, Pierre Ferret
  • Patent number: 10551380
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 4, 2020
    Assignee: Cellestis Limited
    Inventors: Jeff Boyle, Emily Manktelow
  • Patent number: 10551389
    Abstract: Methods of identifying target binding molecules by target guided synthesis are provided. The methods include providing two or more fragments capable of reacting to form the target binding molecule and mixing the fragments with the target. The methods can be used to identify target binding molecules that bind targets such as proteins or nucleic acids, including those that bind shallow binding pockets on the surface of such targets. The methods are applied to the Bcl-XL and Mcl-1 proteins from the Bcl-2 family of proteins. Using thio acid and sulfonyl azide fragments capable of reacting through sulfo-click chemistry, new acyl sulfonamides are identified that bind one or both of the Bcl-XL and Mcl-1 proteins. Pharmaceutical formulations of these target binding molecules are also provided.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: February 4, 2020
    Assignees: University of South Florida, The Penn State Research Foundation
    Inventors: Roman Manetsch, Katya Pavlova Nacheva, David Lawrence Flanigan, Niranjan Kumar Namelikonda, Iredia David Iyamu, Sameer Shamrao Kulkarni, Megan M. Barber, Jeremiah Dwayne Tipton, Hong-Gang Wang, Kenichiro Doi
  • Patent number: 10540536
    Abstract: Imaging mass spectrometry (IMS) has become a prime tool for studying the distribution of biomolecules in tissue. Although IMS data sets can become very large, computational methods have made it practically feasible to search these experiments for relevant findings. However, these methods lack access to an important source of information that many human interpretations rely upon: anatomical insight. In this work, this need is addressed by (1) integrating a curated anatomical data source with an empirically acquired IMS data source, establishing an algorithm-accessible link between them; and (2) demonstrating the potential of such an IMS-anatomical atlas link by applying it toward automated anatomical interpretation of ion distributions in tissue.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: January 21, 2020
    Assignees: Katholieke Universiteit Leuven, K.U.Leuven R&D, Vanderbilt University
    Inventors: Richard M. Caprioli, Bart De Moor, Raf Van De Plas, Nico Verbeeck, Etienne Waelkens
  • Patent number: 10537609
    Abstract: Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 21, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Erik P. Lillehoj, Avelino C. Verceles, Simeon E. Goldblum
  • Patent number: 10539557
    Abstract: Antibodies, immunoassay methods and kits for the detection and determination of 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: January 21, 2020
    Assignee: Randox Laboratories Ltd.
    Inventors: Elouard Benchikh, Ivan McConnell, Peter FitzGerald, Philip Lowry
  • Patent number: 10526387
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 7, 2020
    Assignees: BIONTECH PROTEIN THERAPEUTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Patent number: 10526582
    Abstract: The present disclosure relates generally to the fields of tissue engineering and regenerative medicine. More particularly, the present disclosure generally relates to systems, methods, compositions and kits to rapidly fabricate functionalized three-dimensional tissues from multiple stacks of cell sheets using enzyme-digestible hydrogel substrates as supports for the cell sheets. Methods to generate the multi-layered cell constructs comprise contacting a cell-sheet on one digestible substrate with another cell-sheet on a different digestible substrate, enzymatically digesting with a first enzyme to remove the first substrate and subsequently adding repeating the steps to add another cell-sheet on same digestible substrate to form a multi-layered cell construct as disclosed herein. Additional aspects relate to using the multi-layered cell constructs for therapeutic use, research and in screening assays.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: January 7, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Joshua Jaeyun Kim, Joyce Yun-Wei Wong
  • Patent number: 10517861
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 31, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • Patent number: 10520513
    Abstract: The invention relates to a method for differentiating ischemic stroke from hemorrhagic stroke in a patient and to a method for selecting a patient suffering stroke for a therapy with an antithrombotic agent or with an agent capable of reducing blood pressure based on the determination of the level of GFAP in a sample of said patient in combination with one or more markers selected from the group consisting of NEF3, ?-synuclein, CARNS1 and RBP4, or based on determining the level of RBP4 in a sample of said patient. Furthermore, the invention relates to a kit comprising a reagent for detecting the level of a marker selected from GFAP NEF3, ?-synuclein, CARNS1, RBP4 or a combination thereof and to the use of the said kit in the methods of the invention.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 31, 2019
    Assignee: Fundació Hospital Universitari Vall D'Hebron-Institut De Recerca
    Inventors: Joan Montaner Viallonga, Victor Llombart Sebastiá
  • Patent number: 10513552
    Abstract: The present invention provides a polyclonal antibody composition prepared from eggs of hens immunized with virulent antigens of Clostridium difficile for use in the treatment and prevention of C. difficile infections in subjects with Inflammatory Bowel Disease including Ulcerative colitis and Crohn's disease. Respective groups of hens are immunized with Toxin A or Toxin B of Clostridium difficile or a Clostridium difficile spore preparation. The polyclonal antibodies are recovered from eggs pooled from the immunized hens and the resulting antibody-egg powder is administered orally in a therapeutically effective amount to individuals infected with or suspected of being infected with C. difficile.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 24, 2019
    Assignee: IMMUNIMED INC.
    Inventor: Pradip K. Maiti
  • Patent number: 10509042
    Abstract: The present teachings relate to methods, systems, and kits for analyzing a sample containing a glycopeptide of interest that can subject the glycopeptide of interest to a plurality of parallel deglycosylation reactions that differentially cleave the glycan, with the various products resulting from the deglycosylation reactions being differentially labeled (e.g., with isobaric and/or isomeric labeling reagents) to thereby produce labeled glycopeptides or labeled fragments of the glycopeptides. The products of the various deglycosylation reactions can then be mixed together and subject to LC-MS/MS using a single injection of the mixture. In accordance with various aspects, by associating the resulting mass spectral data with a particular deglycosylation reaction (e.g., based on the presence in the MS/MS data of product reporter ions associated with the particular differential labels), the methods and systems described herein can aid in the identification of the glycan structure.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 17, 2019
    Assignee: DH Technologies Development Pte. Ltd.
    Inventor: David Cox
  • Patent number: 10497104
    Abstract: An automated process empirically normalizes a “dark” image by adjusting the apparent exposure to compensate for nonlinearity in the luminance response of the image sensor. The process includes receiving at least two digital images, one of the digital images having an exposure value that is greater than that of another of the digital images. A reduced-resolution pair of images is produced from the at least two digital images. At least one representative scale factor is calculated from tonal values in the two images and at least one empirical scale factor is determined by selective interpolation between the representative scale factor and a comparative scale factor. The empirical scale factor is used in a function applied pixelwise to the darker of the digital images to produce an empirically normalized digital image.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: December 3, 2019
    Assignee: Adobe Inc.
    Inventor: Richard Case
  • Patent number: 10495649
    Abstract: The present invention relates to a polypeptide carrying a human BNP(1-32) epitope according to Formula (I): a1-R1—X1—FGRKMDR—X2—R2-a2 as well as ligands specific of the FGRKMDR epitope.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 3, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), BIO-RAD EUROPE GMBH
    Inventors: Francois Rieunier, Isabelle Giuliani, Sylvie Villard-Saussine
  • Patent number: 10487129
    Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: November 26, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Gregory Bird
  • Patent number: 10478473
    Abstract: The present invention provides compositions and methods for the treatment of subjects with impaired fertility or at risk for impaired fertility. In certain aspects, the invention relates to increasing the level or activity of anti-Mullerian hormone (AMH) in a subject.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: November 19, 2019
    Assignees: THE CENTER FOR HUMAN REPRODUCTION (CHR), UNIVERSITY OF ROCHESTER
    Inventors: Aritro Sen, Norbert Gleicher, Vitaly A. Kushnir
  • Patent number: 10481144
    Abstract: The invention relates to devices and methods for nanopore sequencing. The invention provides devices having an array of nanopores. The devices comprise an upper fluidic region in fluidic contact with the nanopores. The upper fluidic region comprises and upper electrode. Below each nanopore, and in fluidic contact with each nanopore is a discrete fluidic region. There is no direct fluidic contact between these discrete fluidic regions. The devices have an advantage of lower levels of electrical cross-talk between nanopores in the array for improved nucleic acid sequencing.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: November 19, 2019
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Stephen Turner, Benjamin Flusberg
  • Patent number: 10479838
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 19, 2019
    Assignees: Bristol-Myers Squibb Company, The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • Patent number: 10473669
    Abstract: Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 12, 2019
    Assignee: Nogra Pharma Limited
    Inventor: Giovanni Monteleone
  • Patent number: 10472426
    Abstract: The present disclosure provides a binding protein comprising: a polypeptide heavy chain comprising: VH1-(X1)n-VH2—CH (X2)y wherein VH1 is a first variable domain, VH2 is a second variable domain, CH is a constant domain, X1 represents an amino acid or peptide, X2 represents an Fc region, n is 0 or 1 and y is independently 1 or 2, and a polypeptide light chain comprising: VL1-(X1)n-VL2-C wherein VL1 is a first variable domain, VL2 is a second variable domain, C is a constant domain, X1 represents an amino acid or peptide and n is 0 or 1, wherein the heavy chain and light chain are aligned such that VH1 and VL1 form a first binding domain, and VH2 and VL2 form a second binding domain and wherein: there is a disulfide bond between VH1 and VL1, and/or there is a disulfide bond between VH2 and VL2, and use thereof in treatment.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: November 12, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, David Paul Humphreys
  • Patent number: 10465236
    Abstract: A method and kit for detecting a target nucleic acid is provided wherein combining an amplified nucleic acid with a particle such as a paramagnetic bead form a flocculated complex which can be detected by visual inspection. The volume of nucleic acid sample that can be detected is as low as a few microlitres. The method can be applied to in-the-field or point-of-care diagnosis for a rapid determination of the presence or absence of the target nucleic acid. The methylation status of a target nucleic acid can also be determined. The method and lit may have general applicability to detecting diseases in plants and animals, environmental testing and testing for contamination of foods and other edible products.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 5, 2019
    Assignee: University of Queensland
    Inventors: Matt Trau, Eugene Wee, Jose Ramon Botella
  • Patent number: 10466246
    Abstract: The present invention is drawn to nucleic acid aptamer based signaling polynucleotides (SPNs) for allergen detection in samples. Disclosed herein include compositions, compounds, assays and methods of using said SPNs to detect one or more allergens in a sample, particularly food allergens in a food product.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: November 5, 2019
    Assignee: DOTS TECHNOLOGY CORP.
    Inventor: Adi Gilboa-Geffen
  • Patent number: 10458892
    Abstract: An apparatus for monitoring particulate matter includes a fluid flow passage. Some embodiments include a cartridge defining a part of the fluid flow passage extending from a cartridge inlet to a cartridge outlet and a particle size selector in the fluid-flow passage between the cartridge inlet and the cartridge outlet. The particle size selector comprises a curve section in the fluid flow passage where the flow of fluid undergoes a change in direction and an impact surface extending transversely to the fluid flow passage on an outside of the curve. A particle counter is located downstream from the particle size selector. A pump is connected to drive a flow of a fluid containing the particulate matter through the fluid flow passage. The apparatus may be made compact. Embodiments may be worn and used to monitor exposure of persons to particulate matter.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: October 29, 2019
    Assignee: The University of British Columbia
    Inventors: Boris Stoeber, Winnie Chu, Leon Yuen
  • Patent number: 10456443
    Abstract: Improved calcineurin inhibitors and methods of using these improved calcineurin inhibitors to inhibit calcineurin-NFAT signaling in cells and in subjects are disclosed.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: October 29, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian, John W Christman, Manjula Karpurapu
  • Patent number: 10457743
    Abstract: The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: October 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Jes Thorn Clausen, Berit Olsen Krogh, Helle Heibroch Petersen, Cecilia Augustsson
  • Patent number: 10457746
    Abstract: The present invention relates to the interaction between JMJD6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and JMJD6 protein, in particular the invention relates to a new monoclonal antibody that recognizes JMJD6 and is able to block this interaction.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 29, 2019
    Assignee: FONDAZIONE IRCCS “INSTITUTO NAZIONALE DEI TUMORI”
    Inventors: Mario Paolo Colombo, Silvia Miotti, Elda Tagliabue, Sabina Sangaletti